Dr. Thomas U. Marron, M.D. PH.D.

Medicare patients and services

Medicare patients, 2024

69

Services billed

213

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 31 payments worth $22,844 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 9 companies. The companies reported $2,093,087 in research payments for these studies, mostly to the institutions running them.

• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03916627
• A Phase 1,2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib …
  Merck Sharp & Dohme LLC
• SRF388-101
  Coherus Oncology, Inc.
• A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
  AstraZeneca Pharmaceuticals LP
• Phase 1 Dose-Escalation Study of XB628 in Recurrent Advanced or Metastatic Solid Tumors
  Exelixis Inc.
• An open-label, multicenter, dose escalation and expansion phase 1,2 study to evaluate the safety, tolerability and pharmacokinetics, and anti-tumor activity of GI-102, a CD80-IgG4 Fc-IL-2v bispecific fusion protein, a…
  Merck Sharp & Dohme LLC
• Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
  Genentech, Inc.
• A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
  E.r. Squibb & Sons, L.l.c.
• A phase two, multicohort neoadjuvant study of nivolumab in combination with a dual chemokine receptor two and chemokine receptor five antagonist or an interleukineight antibody in patients with nonsmall cell lung canc…
  E.r. Squibb & Sons, L.l.c.
• A Phase I open label study to assess safety, feasibility, efficacy, and biological activity of single administration of neoadjuvant treatments Ezabenlimab in combination with BI 765063 and Pembrolizumab in combination…
  Boehringer Ingelheim Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

• Ghassan K. Abou-alfa, MD
• Nour Abuhadra
• Melissa Accordino
• David H. Aggen, M.D., PH.D.
• Carol Aghajanian, MD
• Omobolaji O. Akala, MD/PHD
• Duaa H. Al Rawi, MD PHD
• Louis M. Aledort, MD